Peculiarities of the influenza and ARVI viruses circulation during epidemic season 2019–2020 in some regions of Russia

D. K. L’vov; Львов Д. К.; E. I. Burtseva; Бурцева Е. И.; L. V. Kolobukhina; Колобухина Л. В.; I. T. Fedyakina; Федякина И. Т.; N. V. Bovin; Бовин Н. В.; A. V. Ignatjeva; Игнатьева А. В.; K. G. Krasnoslobodtsev; Краснослободцев К. Г.; E. L. Feodoritova; Феодоритова Е. Л.; S. V. Trushakova; Трушакова С. В.; N. V. Breslav; Бреслав Н. В.; L. N. Merkulova; Меркулова Л, Н.; E. A. Mukasheva; Мукашева Е. А.; I. N. Khlopova; Хлопова И. Н.; O. L. Voronina; Воронина О. Л.; E. I. Aksyonova; Аксёнова Е. И.; M. S. Kunda; Кунда М. С.; N. N. Ryzhova; Рыжова Н. Н.; R. V. Vartanjan; Вартанян Н. В.; L. B. Kistenyova; Кистенёва Л. Б.; I. M. Kirillov; Кириллов И. М.; E. S. Proshina; Прошина Е. С.; A. G. Rosatkevich; Росаткевич А. Г.; I. S. Kruzhkova; Кружкова И. С.; A. L. Zaplatnikov; Заплатников А. Л.; M. V. Bazarova; Базарова М. В.; S. V. Smetanina; Сметанина С. В.; M. V. Kharlamov; Харламов М. В.; N. L. Karpov; Карпов Н. Л.; A. V. Shikhin; Шихин А. В.

doi:10.36233/0507-4088-2020-65-6-4

Peculiarities of the influenza and ARVI viruses circulation during epidemic season 2019–2020 in some regions of Russia

Authors: L’vov D.K.¹, Burtseva E.I.¹, Kolobukhina L.V.¹, Fedyakina I.T.¹, Bovin N.V.², Ignatjeva A.V.¹, Krasnoslobodtsev K.G.¹, Feodoritova E.L.¹, Trushakova S.V.¹, Breslav N.V.¹, Merkulova L.N.¹, Mukasheva E.A.¹, Khlopova I.N.¹, Voronina O.L.¹, Aksyonova E.I.¹, Kunda M.S.¹, Ryzhova N.N.¹, Vartanjan R.V.¹, Kistenyova L.B.¹, Kirillov I.M.¹, Proshina E.S.¹, Rosatkevich A.G.¹, Kruzhkova I.S.¹, Zaplatnikov A.L.³, Bazarova M.V.⁴, Smetanina S.V.⁴, Kharlamov M.V.⁵, Karpov N.L.⁶, Shikhin A.V.⁷
Affiliations:
1. FSBI «National Research Centre of Epidemiology and Microbiology named after honorary academician N.F. Gamaleya» of the Ministry of Health of Russia
2. Institute of Bioorganic Chemistry named after academicians M.M. Shemyakin and Yu.A. Ovchinnikov of the Russian Academy of Sciences
3. FSBO DPE Russian Academy of Continuous Professional Education of the Ministry of Health of Russia
4. Clinical Hospital for Infectious Diseases №1 of the Department of Health of Moscow
5. FBIH «Center of hygiene and epidemiology in Novgorod region»
6. FBIH «Center of hygiene and epidemiology in Yaroslavl’ region»
7. FBIH «Center of hygiene and epidemiology in Tomsk region»
Issue: Vol 65, No 6 (2020)
Pages: 335-349
Section: ORIGINAL RESEARCH
URL: https://bakhtiniada.ru/0507-4088/article/view/118143
DOI: https://doi.org/10.36233/0507-4088-2020-65-6-4
ID: 118143

Cite item

Full Text

Abstract
Full Text
About the authors
References
Supplementary files
Statistics

Abstract

Introduction. The surveillance of influenza viruses in ARVI structure and study of their properties in epidemic season 2019–2020 in Russian Federation are actual for investigations due to tasks of Global Influenza Strategy initiated by WHO in 2019.

Material and methods. The data of epidemiological surveillance on influenza- and ARVI-associated morbidity and hospitalization in different age groups of population were analyzed; virological, genetic and statistical methods were used.

Results. Preschool children were involved in epidemic the most. Meanwhile, the highest rate of hospitalization was observed in patients of 18–40 years old. Influenza A(H1N1)pdm09 virus dominated in etiology of ARVI in hospitalized patients and pneumonia. The role of respiratory viruses in severe cases of pneumonia and bronchoalveolar syndrome in children was shown. The differences in spectrum of circulating viruses caused ARVI in different regions of Russia were found. Influenza A(H1N1)pdm09 and B/Victoria-like viruses were the main etiological agents that caused of epidemic; its activity among all ARVI was 7.3 and 8.0%, respectively. The differences in antigenic properties of influenza A(H3N2) and B epidemic strains compared to vaccine viruses were found. The populations of epidemic strains were presented by following dominant genetic groups: 6B1.A5/183P for A(H1N1)pdm09, 3С.2а1b+137F for A(H3N2) and V1A.3 line B/Victoria-like for B viruses. The good profile of epidemic strains susceptibility to anti-neuraminidase inhibitors has been saved. The most of the studied influenza strains had the receptor specificity characteristic of human influenza viruses.

Conclusions. Obtained results identified the peculiarities of viruses caused the influenza and ARVI in epidemic season 2019–2020 in different regions of Russia. These results suggested the important role of influenza A(H1N1) pdm09 in severe cases and pneumonia in adults 18–40 years old. The continuing drift in influenza viruses was found, which, apparently, could not but affect the efficacy of vaccine prophylaxis and was also considered in the recommendations of WHO experts on the composition of influenza vaccines for the countries of the Northern Hemisphere in the 2020–2021 season.

Keywords

epidemic season 2019–2020, ARVI, influenza, biologic and genetic properties, WHO recommended composition of influenza virus vaccines for use in the 2020–2021

Full Text

##article.viewOnOriginalSite##

About the authors

D. K. L’vov

FSBI «National Research Centre of Epidemiology and Microbiology named after honorary academician N.F. Gamaleya» of the Ministry of Health of Russia

Author for correspondence.
Email: dk_lvov@mail.ru
ORCID iD: 0000-0001-8176-6582

D.Sci. (Med.), Prof., Academician of the Russian Academy of Sciences, Head of Department of Ecology of Viruses with Center of Ecology and Epidemiology of Influenza, D.I. Ivanovsky Institute of Virology

123098, Moscow

Russian Federation

E. I. Burtseva

FSBI «National Research Centre of Epidemiology and Microbiology named after honorary academician N.F. Gamaleya» of the Ministry of Health of Russia

Email: elena-burtseva@yandex.ru
ORCID iD: 0000-0003-2518-6801

D.Sci. (Med.), Head of Etiology and Epidemiology of Influenza Laboratory, D.I. Ivanovsky Institute of Virology

123098, Moscow

Russian Federation

References

King A.M., Adams M.J., Carstens E.B., Lefkowitz E.J., eds. Virus Taxonomy. London: Academic Press Elsevier; 2012.
Львов Д.К., ред. Руководство по вирусологии. Вирусы и вирусные инфекции человека и животных. М.: МИА; 2013.
WHO. Global Influenza Strategy 2019–2020. Available at: https://apps.who.int/iris/handle/10665/311184.
WHO. Avian and other zoonotic influenza. Available at: http://www.who.int/influenza/human_animal_interface/.
Dawood F.S., Jain S., Finelli L., Shaw M.W., Lindstrom S., Garten R.J., et al. Emergence of a novel swine-origin influenza A(H1N1) virus in humans. N. Engl. J. Med. 2009; 360(25): 2605–15. https://doi.org/10.1056/nejmoa0903810.
Львов Д.К., Альховский С.В., Колобухина Л.В., Бурцева Е.И. Этиология эпидемической вспышки COVID-19 в г. Ухань (провинция Хубэй, Китайская Народная Республика), ассоциированной с вирусом 2019-nCoV (Nodovirales, Coronaviridae, Coronavirinae, Betacoronavirus, подрод Sarbecovirus): уроки эпидемии SARS-CoV. Вопросы вирусологии. 2020; 65(1): 6–15. https://doi.org/10.36233/0507-4088-2020-65-1-6-15.
Львов Д.К., Альховский С.В. Истоки пандемии COVID-19: экология и генетика коронавирусов (Betacoronavirus: Coronaviridae) SARS-CoV, SARS-CoV-2 (подрод Sarbecovirus), MERSCoV (подрод Merbecovirus). Вопросы вирусологии. 2020; 65(2):62–70. https://doi.org/10.36233/0507-4088-2020-65-2-62-70.
Львов Д.К., Бурцева Е.И., Мукашева Е.А., Колобухина Л.В., Трушакова С.В., Бреслав Н.В. и др. Активность вирусов гриппа в сезоне 2017–2018 гг. в России и странах Северного полушария: конфликт по В-вирусному компоненту вакцин. Эпидемиология и вакцинопрофилактика. 2019; 18(3): 13–21. https://doi.org/10.31631/2073-3046-2019-18-3-13-21.
Львов Д.К., Щелканов М.Ю., Бовин Н.В., Малышев Н.А., Чучалин А.Г., Колобухина Л.В. и др. Корреляция между рецепторной специфичностью штаммов пандемического вируса гриппа A(H1N1)pdm09, изолированных в 2009–2011 гг., структурой рецептор-связывающего сайта и вероятностью развития летальной первичной вирусной пневмонии. Вопросы вирусологии. 2012; 57(1): 14–20.
Rogers G.N., Paulson J.C. Receptor determinants of human and animal influenza virus isolates: differences in receptor specificity of the H3 hemagglutinin based on species of origin. Virology. 1983; 127(2): 361–73. https://doi.org/10.1016/0042-6822(83)90150-2.
Zhou B., Donnelly M.E., Scholes D.T., Hatta M., Kawaoka Y., Wentworth D.E. Single-reaction genomic amplification accelerates sequencing and vaccine production for classical and Swine origin human influenza A viruses. J. Virol. 2009; 83(19): 10309–13. https://doi.org/10.1128/JVI.01109-09.
Zhou B., Lin X., Wang W., Halpin R.A., Stockwell T.B., Barr I.G., et al. Universal Influenza B Virus Genomic Amplification Facilitates Sequencing, Diagnostics, and Reverse Genetics. J. Clin. Microbiol. 2014; 52(5): 1330–7. https://doi.org/10.1128/JCM.03265-13.
Tamura K., Stecher G., Peterson D., Filipski A., Kumar S. MEGA6: Molecular Evolutionary Genetics Analysis Version 6.0. Mol. Biol. Evol. 2013; 30(12): 2725–9. https://doi.org/10.1093/molbev/mst197.
Hadfield J., Megill C., Bell S.M., Huddleston J., Potter B., Callender C., et al. Nextstrain: real-time tracking of pathogen evolution. Bioinformatics. 2018; 34(23): 4121–3. https://doi.org/10.1093/bioinformatics/bty407.
Lakdawala S.S., Jayaraman A., Halpin R.A., Lamirande E.W., Shih A.R., Stockwell T.B., et al. The soft palate is an important site of adaptation for transmissible influenza viruses. Nature. 2015; 526(7571): 122–5. https://doi.org/10.1038/nature15379.
Walther T., Karamanska R., Chan R.W., Chan M.C., Jia N., Air G., et al. Glycomic analysis of human respiratory tract tissues and correlation with influenza virus infection. PLoS Pathog. 2013; 9(3):e1003223. https://doi.org/10.1371/journal.ppat.1003223.
Львов Д.К., Богданова В.С., Кириллов И.М., Щелканов М.Ю., Бурцева Е.И., Бовин Н.В. и др. Эволюция пандемического вируса гриппа A(H1N1)pdm09 в 2009–2016 гг.: динамика рецепторной специфичности первой субъединицы гемагглютинина (НА1). Вопросы вирусологии. 2019; 64(2): 63–72. https://doi.org/10.18821/0507-4088-2019-64-2-63-72.
Finkelstein D.B., Mukatira S., Mehta P.K., Obenauer J.C., Su X., Webster R.G., et al. Persistent host markers in pandemic and H5N1 influenza viruses. J. Virol. 2007; 81(19): 10292–9. https://doi.org/10.1128/JVI.00921-07.
Miotto O., Heiny A., Tan T.W., August J.T., Brusic V. Identification of human-to-human transmissibility factors in PB2 proteins of influenza A by large-scale mutual information analysis. BMC Bioinformatics. 2008; 9(Suppl. 1): S18. https://doi.org/10.1186/1471-2105-9-S1-S18.
WHO. Influenza updates. Available at: https://www.who.int/influenza/surveillance_monitoring/updates/.
WHO. FluNet Summary. Available at: https://www.who.int/influenza/gisrs_laboratory/updates/summaryreport/.
Joint ECDC-WHO/Europe weekly influenza updates. Available at: https://www.flunewseurope.org/.
Weekly U.S. Influenza Surveillance Reports (FluView). Available at: https://www.cdc.gov/flu/weekly/index.htm.
Kawaguchi N., Koshimichi H., Wajimer T. Evaluation of drug-drug interaction potential between baloxavir marboxil and oseltamivir in health subjects. Clin. Drug. Investig. 2018; 38(1): 1053–60. https://doi.org/10.1007/s40261-018-0697-2.
Hayden F.G., Sugaya N., Hirotsu N., Lee N., de Jong M.D., Hurt A.C., et al. Baloxavir marboxil for uncomplicated influenza in adults and adolescents. N. Eng. J. Med. 2018; 379(10): 913–23. https://doi.org/10.1056/nejmoa1716197.
FDA prescribing information: XOFLUZATM (baloxavir marboxil) tablets for oral use. Initial U.S. Approval: 2018. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210854s000lbl.pdf.
WHO. Recommended composition of influenza virus vaccines for use in the 2020–2021 northern hemisphere influenza season. Available at: https://www.who.int/influenza/vaccines/virus/recommendations/2020-21_north/.
ВОЗ. Коронавирус Ближневосточного респираторного синдрома (БВРС-КоВ). Available at: https://www.who.int/features/qa/mers-cov/ru/.
ВОЗ. Коронавирус COVID-19. Available at: https://www.who.int/ru/emergencies/diseases/novel-coronavirus-2019.

Supplementary files

Supplementary Files

Action

1. JATS XML

Download

Username
Password
Remember me

Forgot password?	Register

Username
Password
Remember me

Forgot password?	Register